Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roderich E Schwarz

Showing results (51-60 of 109) with videos related to

Pageof 11
Sort By:
Oncotarget|February 14, 2018
Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancerNiranjan Awasthi, Sheena Monahan, Alexis Stefaniak, et al.
Experimental Cell Research|October 27, 2005
Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrinMargaret A Schwarz, Hiahua Zheng, Jie Liu, et al.
Surgery|July 25, 2009
An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancerRoderich E Schwarz, Srivani Konduri, Niranjan Awasthi, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 13, 2008
Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signalingNiranjan Awasthi, Margaret A Schwarz, Varun Verma, et al.
Molecular Cancer Therapeutics|October 11, 2012
BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancerNiranjan Awasthi, Changhua Zhang, Winston Ruan, et al.
Plos One|March 14, 2012
Cell proliferation and migration are modulated by Cdk-1-phosphorylated endothelial-monocyte activating polypeptide IIMargaret A Schwarz, Janet Thornton, Haiming Xu, et al.
Plos One|March 6, 2013
Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancerChanghua Zhang, Niranjan Awasthi, Margaret A Schwarz, et al.
Plos One|June 23, 2012
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancerNiranjan Awasthi, Changhua Zhang, Winston Ruan, et al.
Cancer Letters|December 21, 2014
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancerNiranjan Awasthi, Stefan Hinz, Rolf A Brekken, et al.
The Journal of Biological Chemistry|March 1, 2015
The N terminus of pro-endothelial monocyte-activating polypeptide II (EMAP II) regulates its binding with the C terminus, arginyl-tRNA synthetase, and neurofilament light proteinHaiming Xu, Nikolay L Malinin, Niranjan Awasthi, et al.
Pageof 11

Showing results (51-60 of 109) with videos related to

Sort By:
Pageof 11
Oncotarget|February 14, 2018
Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancerNiranjan Awasthi, Sheena Monahan, Alexis Stefaniak, et al.
Experimental Cell Research|October 27, 2005
Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta1 integrinMargaret A Schwarz, Hiahua Zheng, Jie Liu, et al.
Surgery|July 25, 2009
An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancerRoderich E Schwarz, Srivani Konduri, Niranjan Awasthi, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 13, 2008
Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signalingNiranjan Awasthi, Margaret A Schwarz, Varun Verma, et al.
Molecular Cancer Therapeutics|October 11, 2012
BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancerNiranjan Awasthi, Changhua Zhang, Winston Ruan, et al.
Plos One|March 14, 2012
Cell proliferation and migration are modulated by Cdk-1-phosphorylated endothelial-monocyte activating polypeptide IIMargaret A Schwarz, Janet Thornton, Haiming Xu, et al.
Plos One|March 6, 2013
Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancerChanghua Zhang, Niranjan Awasthi, Margaret A Schwarz, et al.
Plos One|June 23, 2012
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancerNiranjan Awasthi, Changhua Zhang, Winston Ruan, et al.
Cancer Letters|December 21, 2014
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancerNiranjan Awasthi, Stefan Hinz, Rolf A Brekken, et al.
The Journal of Biological Chemistry|March 1, 2015
The N terminus of pro-endothelial monocyte-activating polypeptide II (EMAP II) regulates its binding with the C terminus, arginyl-tRNA synthetase, and neurofilament light proteinHaiming Xu, Nikolay L Malinin, Niranjan Awasthi, et al.
Pageof 11